Skip to main content
OpenTrials
Completed

NCT Number: NCT06109415

A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE.

This is a Phase 4, randomized, blinded, active-controlled, multicohort study to evaluate HTX-011 compared with bupivacaine HCl in subjects undergoing Total Shoulder Arthroplasty (TSA) (Cohort 1).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Woodland International Research Group, LLC, Little Rock, Arkansas, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Has American Society of Anesthesiologists (ASA) Physical Status of I, II, or III.
  • Is scheduled to undergo a unilateral Total Shoulder Arthroplasty.

Exclusion criteria

  • Is undergoing a revision surgery.
  • Has a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to bupivacaine (or other local anesthetics), NSAIDs, acetaminophen, oxycodone, morphine, or hydromorphone.
  • History of severe allergic reaction to aspirin or other NSAIDs, or known history of severe gastrointestinal adverse reactions associated with NSAID use.
  • Has taken meloxicam within 10 days prior to the scheduled surgery, or any NSAID within 24 hours prior to the scheduled surgery, with the exception of subjects on low-dose (≤100 mg) daily acetylsalicylic acid for cardioprotection.
  • Opioid use for most days within the last 3 months prior to Screening in the opinion of the Investigator.
  • Has been administered immediate-release bupivacaine HCl within 5 days prior to the scheduled surgery, or a modified-release bupivacaine product within 14 days prior to the scheduled surgery.
  • Has initiated treatment with any of the following medications within 1 month prior to study drug administration: selective serotonin reuptake inhibitors, selective norepinephrine reuptake inhibitors, gabapentin, pregabalin, duloxetine, or cyclooxygenase-2 inhibitors.
  • Has been administered systemic steroids within 5 half-lives or 10 days prior to the scheduled surgery (whichever is longer).
  • Has a known or suspected history of drug abuse, a positive drug screen (except for cannabinoids) on the day of surgery, or a history of alcohol abuse within the past 5 years.
  • Suspected or confirmed active coronavirus disease 2019 (COVID-19) infection.
  • Had a malignancy in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
  • Has undergone 3 or more surgeries within 12 months, other than for diagnostic procedures (eg, colonoscopy).
  • Has a body mass index (BMI) >40 kg/m2.

Treatment and study plan

HTX-011

Drug

400 mg

Bupivacaine Hydrochloride

Drug

100 mg

Ibuprofen

Drug

400 mg

Acetaminophen

Drug

1 g

Luer Lock Applicator

Device

Applicator for instillation

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs).

    Time frame: Through Day 15

Secondary outcomes

  1. Maximum concentration (Cmax) of bupivacaine and meloxicam

    Time frame: Through 144 hours

  2. Time of occurrence of maximum concentration (Tmax) of bupivacaine and meloxicam

    Time frame: Through 144 hours

  3. Area under the concentration-time curve from Time 0 to the time of the last quantifiable concentration (AUClast) of bupivacaine and meloxicam

    Time frame: Through 144 hours

  4. Area under the concentration-time curve from Time 0 extrapolated to infinity (AUCinf) of bupivacaine and meloxicam

    Time frame: Through 144 hours

  5. Apparent terminal half-life (t½) of bupivacaine and meloxicam

    Time frame: Through 144 hours

Sponsors and collaborators

Lead sponsor

Heron Therapeutics

Industry

Registry information

Official study title

A Phase 4, Randomized, Blinded, Active-Controlled Study of HTX-011 in Subjects Undergoing Total Shoulder Arthroplasty (TSA)

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Oct 31, 2023
Registry last updated
Oct 31, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.